Clinical trials: Contrast Enhancement in Magnetic Resonance Imaging, open to volunteers
Breast Cancer
Clinical Effectiveness of CEM in Diagnosis of Additional Findings at Preoperative Breast Magnetic Resonance Imaging
In order to explain the value of adding CESM into the clinical pathway, and also to obtain the relevant clinical data to support future update of clinical guideline, we plan to evaluate the detection rate of CESM for additional…
- Trial name
- COMBO-I (NCT06475066)
- Testing
- contrast-enhanced spectral mammography
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Breast Cancer
Non-inferiority Study of Contrast-enhanced Digital Mammography (CEDM) vs Magnetic Resonance Imaging (MRI) in Terms of Diagnostic Accuracy in Patients Undergoing Preoperative Staging of Established Invasive Breast Cancer
The general objective of the study is to verify the diagnostic accuracy of contrast-enhanced mammography (CEM) compared to breast magnetic resonance imaging in patients undergoing preoperative staging for breast neoformations…
- Trial name
- CEDM-VR (NCT07071272)
- Testing
- breast-MRI and CEM
- Where
- Italy
- Volunteers
- 216 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Pulmonary Hypertension, Elevated Mean Pulmonary Arterial Pressure
Non-contrast Enhanced Cardiac Magnetic Resonance Imaging in the Diagnosis and Classification of Pulmonary Hypertension
Pulmonary hypertension (PH) is a life-threatening cardiovascular disease characterized by pathological elevation of mean pulmonary arterial pressure (mPAP) >/= 25 mmHg at rest.
- Conditions
- Pulmonary Hypertension, Elevated Mean Pulmonary Arterial Pressure, Normal Mean Pulmonary Arterial Pressure
- Trial name
- CMR-PH (NCT01725763)
- Testing
- Cardiac MRI
- Where
- Austria
- Volunteers
- 150 people
- Sponsor
- Medical University of Graz
Kidney Failure, Acute
Non-invasive Evaluation of the Predictive Value of CEUS and SWE in ACLF, Renal Failure and Hepatorenal Syndrome
Evaluation of non-invasive prognostic parameters in patients developing ACLF and renal failure in patients receiving and not receiving transjugular intrahepatic portosystemic shunt (TIPS).
- Trial name
- NECTAR (NCT04446858)
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Bonn
Breast Cancer Screening and Diagnosis
Contrast Enhancement Mammography vs MRI for the Surveillance of Women at High Risk of Breast Cancer: Con-trust Randomized Controlled Trial
Women at high risk of breast cancer (BC) should undergo annual magnetic resonance imaging (MRI) and digital mammography (DM) from at least ages 35 to 60.
- Trial name
- CEM (NCT06629896)
- Testing
- Contrast Enhancement Mammography, magnetic resonance imaging (MRI) and digital mammography (DM)
- Where
- Italy
- Volunteers
- 2,200 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Non-Small Cell Lung Cancer, Brain Metastases
Retrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Status in NSCLC Brain Metastases With External Validation and Survival Analysis
This retrospective multicenter observational study aims to develop and externally validate a noninvasive deep learning model based on routine brain MRI to identify actionable driver alterations in patients with non-small cell…
- Trial name
- DL-DriverBM (NCT07373951)
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Ming Yang
Non Mass Breast Lesions
Diagnostic Accuracy of Multiparametric Dynamic Contrast Enhanced Magnetic Resonance Imaging in Improving Detection of Ultrasound Non-mass Breast Lesions According to ACR BI-RADS v2025
this study aims To evaluate the diagnostic performance of Ultrasound (US) in correlation with Dynamic Magnetic Resonance Imaging (MRI) for the assessment, characterization, and evaluation of non-mass breast lesions.
- Trial name
- NCT07679308
- Testing
- multiparametric DCE- MRI and US for all patients
- Volunteers
- 60 people
- Sponsor
- Sohag University
Head and Neck Cancer
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
This trial studies how well dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) works in diagnosing osteoradionecrosis in patients with head and neck cancer that is primary, has come back, or has spread to other places…
- Trial name
- NCT03145077
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Questionnaire Administration
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- M.D. Anderson Cancer Center
Cirrhosis, Cirrhosis Due to Hepatitis B
Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer
Aim: To use magnetic resonance imaging (MRI) scans without contrast to help improve diagnosis of liver cancer in people who are at increased risk of developing liver cancer.
- Conditions
- Cirrhosis, Cirrhosis Due to Hepatitis B, Cirrhosis and Chronic Liver Disease, Cirrhosis Due to Hepatitis C
- Trial name
- AMULET (NCT06658782)
- Testing
- non contrast enhanced MRI
- Where
- 2 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- University of Oxford
Retinoblastoma
Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?
Retinoblastoma is the most frequent intraocular tumor in children and represents 6% of all pediatric cancers before the age of 5 years-old. The outcome is now excellent with 95 to 97% of 5-years survival rate.
- Trial name
- PREDIR (NCT03267459)
- Testing
- Dynamic contrast-enhanced MRI
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion
A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients
This is an operationally combined Phase 2/3 study, which will be conducted and evaluated in 2 distinct parts: Phase 2: Prospective, adaptive, multicenter, non-randomized, single-blind, dose-finding, including participants with…
- Trial name
- LUMINA (NCT07472491)
- Testing
- Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL, MRI Scan, Gadobutrol
- Where
- 7 sites in United States, Georgia and 2 more
- Volunteers
- 640 people
- Sponsor
- GE Healthcare
Bladder Cancer, Staging
Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale
Bladder cancer is the most common malignant tumor of the urinary system. The presence or absence of muscle invasion in early bladder cancer is an independent prognostic factor.
- Conditions
- Bladder Cancer, Staging, Deep Learning, Neoadjuvant Chemotherapy
- Trial name
- MICS-BC (NCT07051083)
- Testing
- Risk Stratification
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University